Clinical Trial Update: MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin [Phase 3]

View source ↗

Summary

Phase 3 trial MARLINA-T2D evaluated linagliptin for efficacy, safety, and reduction of albuminuria in type 2 diabetes with renal disease; trial completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• Linagliptin (linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2017-03-06